This trial will investigate a novel 3-fraction radiation regimen for participants undergoing breast-conserving therapy (BCT) for early breast cancer that will: 1) significantly reduce the duration of treatment and can be completed in one-week (5 working days) and 2) MRI-guided radiotherapy (MRIdian) would limit the volume of normal tissue radiated and therefore resultant toxicity. The hypothesis is that 3-fraction radiation therapy can be delivered safely without compromising the therapeutic ratio. Participants can expect to be on study for follow up up to 5 years.
| Condition | Ductal Carcinoma In Situ, Adenocarcinoma, Breast Cancer, Breast Cancer Diagnosis, Ductal Carcinoma In Situ (DCIS), Lobular Carcinoma In Situ, Malignant Adenoma, LCIS, breast carcinoma, cancer, breast, dcis |
|---|---|
| Treatment | MRIdian Radiation Treatment Unit |
| Clinical Study Identifier | NCT03936478 |
| Sponsor | University of Wisconsin, Madison |
| Last Modified on | 3 March 2021 |
Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.
Sign up as volunteer
Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!
No annotations made yet
Congrats! You have your own personal workspace now.